

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by **ShenZhen HEPALINK PHARMACEUTICAL GROUP CO., LTD.** (the **Company**, together with its subsidiaries, the **Group**), in accordance with the Inside Information Provisions of the **Securities and Futures Ordinance** (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the **Regulatory Listing Rules** of the **Stock Exchange of Hong Kong Limited** (**Listing Rules**).

The **Board of Directors** (the **Board**) of the **Company** (the **Shareholders**) and the **Chairman**, **TechDow Pharma Italy S.R.L.**, a wholly-owned subsidiary of the **Company** (**TechDow Italy**), in accordance with the **Articles of Association** of the **Company** (the **Articles**) and the **Listing Rules** (the **Incident**). The **Board** has been informed of the **Incident** by the **Chairman** of the **Company**. The **Chairman** has been advised to file a disclosure in accordance with the **Listing Rules**. The **Chairman** has been advised to file a disclosure in accordance with the **Listing Rules**. The **Chairman** has been advised to file a disclosure in accordance with the **Listing Rules**.

The **Chairman** of the **Company** has been advised of the **Incident** by the **Chairman** of the **Company**. The **Chairman** has been advised to file a disclosure in accordance with the **Listing Rules**. The **Chairman** has been advised to file a disclosure in accordance with the **Listing Rules**. The **Chairman** has been advised to file a disclosure in accordance with the **Listing Rules**.

The independent director of the Company, Mr. Li Li, has received the TechLink IAB's handling of the ICD. After the investigation of the ICD in the morning, he has been ill, and has been hospitalized for the Company's financial affairs. He has been hospitalized since December 31, 2023 (FY2023).

The Company's independent director of the ICD in the afternoon and will continue to handle the case and deal with the delay.

The Board has held a meeting of the Board, and has held a meeting of the Board to discuss the financial affairs of the Company.

The Company will take the necessary measures to keep the Shareholders and independent directors informed of the significant developments in the execution of the ICD and the company's financial affairs. The Shareholders and independent directors of the Company are advised to read carefully the annual report of the Company for FY2023 (**Annual Results**), which is expected to be published in March 2024, and the relevant provisions of the Listing Rules, and the relevant financial information in the Annual Report.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
January 15, 2024

As a reminder of his announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Y and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. L Chan, Mr. Hang Peng and Mr. Yi Ming.